DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 32.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 54,825 shares of the medical device company’s stock after selling 26,600 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in DexCom were worth $4,264,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc purchased a new stake in shares of DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA raised its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC lifted its position in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC boosted its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the fourth quarter worth about $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 1.5 %

Shares of DXCM stock opened at $60.69 on Wednesday. The business’s fifty day moving average price is $78.56 and its 200 day moving average price is $76.72. The firm has a market capitalization of $23.80 billion, a PE ratio of 42.44, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $141.99.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Cfra Research raised DexCom to a “hold” rating in a report on Friday, March 21st. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.